Trial aims to tame debilitating side effect of powerful cancer drugs
NCT ID NCT06521762
Summary
This study aimed to see if adding a drug called etrasimod to standard steroid treatment could better control severe diarrhea and colon inflammation (colitis) caused by cancer immunotherapy. It planned to enroll adults with advanced cancer who developed this serious side effect while on certain immunotherapies. The goal was to reduce the amount of steroids needed and help patients get back on their cancer treatment sooner, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-RELATED DIARRHEA AND COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.